FDAnews
www.fdanews.com/articles/197333-puretech-selects-experimental-covid-19-treatment-for-human-trials

PureTech Selects Experimental COVID-19 Treatment for Human Trials

May 29, 2020

PureTech Health said it will begin human trials on an experimental treatment for respiratory complications following recovery from COVID-19 infections.

The treatment, LYT-100 (deupirfenidone), is an analog of the pulmonary fibrosis treatment pirfenidone. It is designed to reduce, delay or prevent the lung dysfunction that has been documented in COVID-19 patients, including in those who have recovered.

The company began a phase 1 trial of the treatment in March, testing its safety and tolerability in healthy participants. It plans to begin further trials of the treatment in the third quarter of this year.

View today's stories